Bruce L. Levine
Built the manufacturing that turned CAR-T from a lab idea into a product given to thousands of patients.
Co-developer of the CTL019 manufacturing process and long-time leader of Penn's cell production facility; past president of the International Society for Cell & Gene Therapy.
| Title | Journal | Year |
|---|---|---|
| Global manufacturing of CAR T cell therapy | Molecular Therapy Methods & Clinical Development | 2017 |
ELIANA turned CAR-T from a single-centre experiment into a licensed product and created the regulatory and logistical template every later cell therapy has followed. For children with refractory leukaemia it offers a chance of durable remission without transplant. The trial also exposed the gaps: manufacturing failures, patients dying while waiting, and roughly half relapsing within a few years.
This paper is the proof-of-concept for a living drug: a single infusion of a patient's own engineered T cells could eradicate leukaemia that had survived chemotherapy, transplant and antibody therapy. It defined cytokine release syndrome and its antidote, tocilizumab, and revealed antigen-loss relapse. It led directly to the first approved gene-modified cell therapy three years later.
Pages like this
not linked directly; found by shared links- PersonCarl H. June
Shares Emily Whitehead, Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, Abramson Cancer Center, University of Pennsylvania.
- PersonDavid L. Porter
Shares Emily Whitehead, Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, Abramson Cancer Center, University of Pennsylvania, CAR-T cell therapy.
- TrialELIANA
Shares Emily Whitehead, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, CAR-T cell therapy.
- PersonDrew Weissman
Shares In vivo CAR-T, Abramson Cancer Center, University of Pennsylvania.
- PersonChristof von Kalle
Shares In vivo CAR-T, CAR-T cell therapy.
- ProductTisagenlecleucel
Shares Emily Whitehead, Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, CAR-T cell therapy.
- CompanyInterius BioTherapeutics
Shares In vivo CAR-T, Abramson Cancer Center, University of Pennsylvania.
- Key paperUCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL
Shares ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, In vivo CAR-T, CAR-T cell therapy.